RT Journal Article
SR Electronic
T1 Differentially Altered Metabolic Pathways in the Amygdala of Subjects with Schizophrenia, Bipolar Disorder and Major Depressive Disorder
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.17.24305854
DO 10.1101/2024.04.17.24305854
A1 Zhang, Xiaolu
A1 Valeri, Jake
A1 Eladawi, Mahmoud A.
A1 Gisabella, Barbara
A1 Garrett, Michael R.
A1 Vallender, Eric J
A1 McCullumsmith, Robert
A1 Pantazopoulos, Harry
A1 O’Donovan, Sinead M.
YR 2024
UL http://medrxiv.org/content/early/2024/04/19/2024.04.17.24305854.abstract
AB Background and hypothesis A growing number of studies implicate a key role for metabolic processes in psychiatric disorders. Recent studies suggest that ketogenic diet may be therapeutically effective for subgroups of people with schizophrenia (SCZ), bipolar disorder (BPD) and possibly major depressive disorder (MDD). Despite this promise, there is currently limited information regarding brain energy metabolism pathways across these disorders, limiting our understanding of how brain metabolic pathways are altered and who may benefit from ketogenic diets. We conducted gene expression profiling on the amygdala, a key region involved in in the regulation of mood and appetitive behaviors, to test the hypothesis that amygdala metabolic pathways are differentially altered between these disorders.Study Design We used a cohort of subjects diagnosed with SCZ, BPD or MDD, and non-psychiatrically ill control subjects (n=15/group), together with our bioinformatic 3-pod analysis consisting of full transcriptome pathway analysis, targeted pathway analysis, leading-edge gene analysis and iLINCS perturbagen analysis.Study Results We identified differential expression of metabolic pathways in each disorder. Subjects with SCZ displayed downregulation of mitochondrial respiration and nucleotide metabolism pathways. In comparison, we observed upregulation of mitochondrial respiration pathways in subjects with MDD, while subjects with BPD displayed enrichment of pathways involved in carbohydrate metabolism. Several pathways associated with brain metabolism including immune system processes and calcium ion transport were also differentially altered between diagnosis groups.Conclusion Our findings suggest metabolic pathways are differentially altered in the amygdala in these disorders, which may impact approaches for therapeutic strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by support from the Baszucki Brain Research Foundation to HP, the NIGMS including the Molecular Center of Health and Disease (P20GM144041) to BG and MRG, and YIG-1-139-20 awarded to SMOD from the American Foundation for Suicide Prevention. The content is solely the responsibility of the authors and does not necessarily represent the official views of the American Foundation for Suicide Prevention. The work performed through the UMMC Molecular and Genomics Facility is supported, in part, by funds from the National Institute of General Medical Sciences (NIGMS), including the Molecular Center of Health and Disease (P20GM144041, MRG), Mississippi INBRE (P20GM103476) and Obesity, Cardiorenal and Metabolic Diseases- COBRE (P30GM149404). BG is supported as research project leaders for P20GM144041.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the Stanley Brain Collection was obtained through the Uniformed Services University of the Health Sciences, Bethesda, MDI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data and original contributions presented in this study are included in the manuscript or supplemental materials. All gene expression data is available from the Stanley Neuropathology Consortium Integrative Database. Further inquiries can be directed to the corresponding authors.